7.24
price up icon0.42%   0.03
after-market Dopo l'orario di chiusura: 7.27 0.03 +0.41%
loading
Precedente Chiudi:
$7.21
Aprire:
$7.1
Volume 24 ore:
2.15M
Relative Volume:
2.63
Capitalizzazione di mercato:
$498.18M
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-3.978
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
+27.46%
1M Prestazione:
+9.04%
6M Prestazione:
-18.19%
1 anno Prestazione:
-32.65%
Intervallo 1D:
Value
$6.8625
$7.58
Intervallo di 1 settimana:
Value
$5.57
$7.58
Portata 52W:
Value
$3.91
$13.98

Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile

Name
Nome
Eyepoint Pharmaceuticals Inc
Name
Telefono
617-926-5000
Name
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Name
Dipendente
144
Name
Cinguettio
@eyepointpharma
Name
Prossima data di guadagno
2025-03-05
Name
Ultimi documenti SEC
Name
EYPT's Discussions on Twitter

Confronta EYPT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
EYPT
Eyepoint Pharmaceuticals Inc
7.24 390.85M 46.02M -70.80M -1.61M -1.82
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-07 Iniziato Citigroup Buy
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-08-28 Iniziato Jefferies Buy
2024-01-22 Iniziato JP Morgan Overweight
2023-11-02 Iniziato Mizuho Buy
2023-04-21 Iniziato Robert W. Baird Outperform
2022-07-07 Iniziato Chardan Capital Markets Buy
2021-03-01 Iniziato Cowen Outperform
2021-01-28 Iniziato Cantor Fitzgerald Overweight
2020-04-06 Downgrade B. Riley FBR Buy → Neutral
2019-11-04 Ripresa Laidlaw Buy
2019-09-12 Iniziato Guggenheim Buy
Mostra tutto

Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie

pulisher
May 30, 2025

EyePoint advances with Duravyu Phase III trial - Yahoo

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com

May 30, 2025
pulisher
May 30, 2025

EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders are up 29% this past week, but still in the red over the last year - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Biggest Companies on Nasdaq EyePoint Pharmaceuticals Insights by Kalkine - Kalkine Media

May 29, 2025
pulisher
May 29, 2025

Analyst Expectations For EyePoint Pharmaceuticals's Future - Benzinga

May 29, 2025
pulisher
May 29, 2025

EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 Price Target | EYPT Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 P - GuruFocus

May 29, 2025
pulisher
May 28, 2025

EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times

May 28, 2025
pulisher
May 28, 2025

EyePoint Secures Triple Conference Spotlight: Goldman Sachs, Jefferies, and Guggenheim Healthcare Events - Stock Titan

May 28, 2025
pulisher
May 27, 2025

EyePoint at Stifel Forum: Strategic Advances in Ophthalmology By Investing.com - Investing.com Canada

May 27, 2025
pulisher
May 27, 2025

JPMorgan maintains EyePoint stock Overweight with $26 target By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

JPMorgan maintains EyePoint stock Overweight with $26 target - Investing.com

May 27, 2025
pulisher
May 27, 2025

Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

EyePoint (EYPT) Surpasses Enrollment Goal in Key Phase 3 Trial | - GuruFocus

May 27, 2025
pulisher
May 27, 2025

EyePoint Completes Enrollment for DURAVYU Phase 3 Trial - TipRanks

May 27, 2025
pulisher
May 27, 2025

EyePoint Pharmaceuticals Reports Rapid Enrollment Progress in Phase 3 LUGANO Trial of DURAVYU™ for Wet AMD Treatment - Nasdaq

May 27, 2025
pulisher
May 27, 2025

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - The Manila Times

May 27, 2025
pulisher
May 26, 2025

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Globe and Mail

May 26, 2025
pulisher
May 19, 2025

Insider Buying: Karen Zaderej Acquires Additional Shares of EyeP - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Insider Buying: Karen Zaderej Acquires Additional Shares of EyePoint Pharmaceuticals Inc (EYPT) - GuruFocus

May 19, 2025
pulisher
May 16, 2025

EyePoint Pharmaceuticals (EYPT) Target Price Lowered by Mizuho Analyst | EYPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint (EYPT) Faces Price Target Reduction by Mizuho | EYPT St - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint price target lowered to $26 from $30 at Mizuho - TipRanks

May 16, 2025
pulisher
May 16, 2025

Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint (EYPT) Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

May 16, 2025
pulisher
May 16, 2025

EyePoint Awards Major Stock Options Package: 7 New Hires Receive 136,700 Shares at $5.72 - Stock Titan

May 16, 2025
pulisher
May 16, 2025

Mizuho cuts EyePoint Pharmaceuticals target to $26 By Investing.com - Investing.com India

May 16, 2025
pulisher
May 16, 2025

Mizuho cuts EyePoint Pharmaceuticals target to $26 - Investing.com

May 16, 2025
pulisher
May 15, 2025

Balyasny Asset Management L.P. Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat

May 15, 2025
pulisher
May 11, 2025

(EYPT) Technical Data - news.stocktradersdaily.com

May 11, 2025
pulisher
May 11, 2025

New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Yahoo Finance

May 11, 2025
pulisher
May 10, 2025

Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo

May 10, 2025
pulisher
May 10, 2025

Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN

May 10, 2025
pulisher
May 08, 2025

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 08, 2025
pulisher
May 08, 2025

EyePoint Pharmaceuticals (EYPT): Analyst Maintains Buy Rating, Lowers Price Target | EYPT Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025
pulisher
May 08, 2025

EyePoint Pharma’s Promising Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals (EYPT) Reports Growth Amidst Trial Developments - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Transcript : EyePoint Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals Q1 2025 Earnings Preview - MSN

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: EyePoint Pharmaceuticals Q1 2025: Revenue Surges - Investing.com

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

EyePoint (EYPT) Sees Strong Q1 Revenue Growth and Advances in DURAVYU Trials | EYPT Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals Inc Surpasses Revenue Estimates with $24.5 Million in Q1 2025, EPS of ($0.65) Slightly Beats Expectations - GuruFocus

May 07, 2025

Eyepoint Pharmaceuticals Inc Azioni (EYPT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):